Fig. 5: The antibacterial application and the ability to inhibit biofilm formation of LacAC4A. | Nature Communications

Fig. 5: The antibacterial application and the ability to inhibit biofilm formation of LacAC4A.

From: Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer

Fig. 5

a The images of remaining bacteria after being treated with PBS, LacAC4A, Cip and Cip@LacAC4A in normoxic and hypoxic conditions, respectively. The quantification of remaining PA 14 (b) and MDR PA (c) after various treatments. d The mechanism schematic of LacAC4A for inhibiting the formation of bacterial biofilm. e CLSM images of LacAC4A for inhibiting the formations of PA 14 and MDR PA biofilms. Scale bar was 50 μm. f Inhibition percentage of MDR PA biofilm formation with various concentrations of LacAC4A. g Inhibition percentage of PA 14 biofilm formation after being treated with various concentrations of LacAC4A. Data are presented as mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page